Private equity firm ChrysCapital plans to increase its spending on healthcare delivery and services, driven by the rising popularity of branded healthcare in India.
ChrysCapital's managing director, Raghav Ramdev, said in an interview that the company plans to invest more in the healthcare sector, which has been overlooked. However, he did not disclose the exact amount of money the company planned to invest.
ChrysCapital has raised and invested in nine private equity funds in India. Centre for Sight is the company's first venture in the private healthcare sector. For about ₹193 crore, it acquired 1.96% of the Hyderabad-based Krishna Institute of Medical Sciences in 2022 from General Atlantic in the public markets.
The company has been very successful with its pharmaceutical investments, making profits from companies like IPCA Laboratories, Torrent Pharma, Curatio Healthcare, GVK Biosciences, and Cadila Healthcare. Former Ranbaxy Laboratories executive partner Sanjiv Kaul is in charge of the company's pharmaceutical portfolio. Additionally, the company has investments in businesses like Intas Laboratories, Eris LifeSciences, and Mankind Pharma.
ChrysCapital will consider deals in different areas of the healthcare sector, including diagnostics, medical devices, and contract development and manufacturing organizations (CDMOs). They also intend to assess opportunities in single-specialty and multi-specialty hospital chains.
With substantial headroom for expansion, ChrysCapital is focusing on single-specialty markets like obstetrics, gynecology, oncology, and ophthalmology.
